Welcome to our dedicated page for Xtant Medical news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical stock.
Xtant Medical Holdings, Inc. reports developments as a medical technology company focused on surgical solutions for spinal and other orthopedic conditions. Its recurring updates include financial results, commercial activity in orthobiologics, and spinal implant systems used in complex spine, deformity, degenerative, wound care, and sports medicine applications.
Company news also covers product portfolio changes such as Trivium bone graft launches, U.S. distribution rights for HEMOBLAST Bellows, and completed divestitures involving Coflex, CoFix, and Paradigm Spine GmbH. These updates track how Xtant manages its biologics-focused portfolio, distribution channels, and surgical-product commercialization.
Xtant Medical (NYSE American: XTNT) reported first quarter 2026 revenue of $20.9 million, down from $32.9 million a year earlier, with gross margin of 57.3% and operating expenses of $14.9 million. Net loss was $3.1 million and adjusted EBITDA loss was $1.6 million.
The company reduced total indebtedness to $12.2 million from $25.4 million and received the final $10.7 million payment from Companion Spine. It raised full-year 2026 revenue guidance to $101–$105 million and entered an exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST Bellows, adding Dilon’s U.S. sales team.
Xtant Medical (NYSE American: XTNT) will release first quarter 2026 financial results for the period ended March 31, 2026, before market open on Wednesday, May 13, 2026. Management will host a conference call at 8:30 AM ET that day; a replay will be posted on the company's investor site.
Conference dial-ins, passcode, webcast link, and replay location are provided for investors and analysts to access the live presentation and subsequent recording.
Xtant Medical (NYSE American: XTNT) announced the commercial launch of Trivium™ Shaped on May 6, 2026, an extension of the Trivium bone graft portfolio offering pre-shaped, ready-to-use forms (boats and strips) for surgical use.
Trivium Shaped builds on the April 2025 sculptable format, uses PureLoc™ automated DBM milling to produce elongated cortical fibers, and is available through Xtant's nationwide independent agent distribution network.
Xtant Medical (NYSE:XTNT) acquired exclusive U.S. distribution rights to Dilon Technologies' HEMOBLAST® Bellows, a pre-loaded hemostatic powder for minimal to moderate surgical bleeding. Xtant will integrate Dilon's approximately 20-person U.S. sales team and aims to expand penetration of an estimated $2.0 billion global hemostatic market.
HEMOBLAST contains collagen, human thrombin, and bovine chondroitin sulfate and requires no prep. Xtant plans to update its full-year 2026 financial guidance when reporting Q1 2026 results.
Xtant Medical (NYSE American: XTNT) announced support for the Threshold of Life Memorial, an outdoor tribute to organ, eye, and tissue donors planned for the Montana State Capitol grounds in Helena. The project is approved for design and location with targeted completion in Summer 2028.
The memorial will feature symbolic elements (water, circular structure, pollinator garden), be funded entirely by private support, and list the Helena Area Community Foundation as fiscal sponsor. The initiative highlights Montana's high donor registration rate of 86%.
Xtant Medical (NYSE:XTNT) reported full-year 2025 revenue of $133.9M, up ~14% year-over-year, with net income of $5.0M and adjusted EBITDA of $16.3M. Cash from operations was $12.5M and cash on hand was $17.3M as of Dec 31, 2025, excluding $10.5M received subsequent to year-end.
The company completed the sale of Coflex, CoFix and international hardware to Companion Spine for $21.4M cash, launched nanOss Strata and CollagenX, and issued 2026 revenue guidance of $95M–$99M.
Xtant Medical (NYSE American: XTNT) will release fourth-quarter and full-year 2025 financial results before trading on Tuesday, March 31, 2026. A conference call with CEO Sean Browne and CFO Scott Neils is scheduled for 8:30 AM ET that day.
Investors can join by dial-in or webcast; a replay will be posted under "Investor info" on the company's website after the live call.
Xtant Medical (NYSE American: XTNT) announced completion of its Companion Spine divestitures after receiving $10.7 million on March 2, 2026, bringing the total aggregate purchase price to $21.4 million for the Coflex assets and Paradigm OUS businesses.
Of the $10.7 million, $8.2 million satisfied an unsecured promissory note (plus accrued interest) and $2.2 million related to working capital and purchase price adjustments. Management said the proceeds will help reduce long-term debt and provide additional cash liquidity while refocusing the company on higher-margin biologics.
Xtant Medical (NYSE: XTNT) said CEO Sean Browne, CFO Scott Neils, and COO Mark Schallenberger will participate in the Canaccord Genuity 2026 Musculoskeletal Conference on March 2, 2026, in New Orleans and virtually. A webcast will be available and management will offer virtual one-on-one meetings. A replay will be posted to Xtant's Presentation & Events page for 90 days.
Xtant Medical (NYSE American: XTNT) announced the commercial launch on December 11, 2025 of its next‑generation synthetic bone graft, nanOss Strata.
nanOss Strata is made from hydroxycarbonapatite (HCA), a more soluble material than traditional hydroxyapatite, and uses a nanocrystalline structure to more closely mimic human bone, increase surface area, improve osteoconductivity, and enhance cellular stimulation for integration and remodeling. Strata is offered as compression‑resistant preformed strips and prehydrated moldable grafts, both sterile, highly moldable, and designed to rapidly absorb blood and biologic fluids. The product is available through Xtant Medical's nationwide distribution network.